[Fragile site on chromosome 2 (q11) in a case of familial lymphohistiocytosis].
After recalling the main studies about the fragile sites, a fra (2) (q11) in a girl with familial lymphohistiocytosis is described. The influence of medicine, inducers, mutagenic agents are analysed.
D015112:4-Nitroquinoline-1-oxide / Q000494:pharmacology; D000328:Adult; D001973:Bromodeoxyuridine / Q000494:pharmacology; D002478:Cells, Cultured; D043283:Chromosome Fragile Sites; D002873:Chromosome Fragility; D002900:Chromosomes, Human, 1-3; D004214:Distamycins / Q000494:pharmacology; D005260:Female; D006801:Humans; D007223:Infant; D007370:Interferon Type I / Q000494:pharmacology; D007621:Karyotyping; D008206:Lymphatic Diseases / Q000150:complications / Q000235:genetics*; D008214:Lymphocytes / Q000187:drug effects; D008218:Lymphocytosis / Q000150:complications / Q000235:genetics*; D008297:Male; D008741:Methyl Methanesulfonate / Q000494:pharmacology
D004214:Distamycins; D007370:Interferon Type I; D015112:4-Nitroquinoline-1-oxide; C030000:stallimycin; D008741:Methyl Methanesulfonate; D001973:Bromodeoxyuridine
Site fragile sur le chromosome 2 (q11) dans un cas de lymphohistiocytose familiale.